Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate.
Kiwamu Okita
Employment or Leadership Position - Shimonoseki Kosei Hospital
Consultant or Advisory Role - Eisai
Honoraria - Eisai
Hiromitsu Kumada
Consultant or Advisory Role - Eisai
Honoraria - Eisai
Research Funding - Eisai
Kenji Ikeda
Consultant or Advisory Role - Eisai
Honoraria - Eisai
Masatoshi Kudo
Honoraria - Eisai
Seiji Kawazoe
No relevant relationships to disclose
Yukio Osaki
Honoraria - Eisai
Masafumi Ikeda
No relevant relationships to disclose
Toshiyuki Tamai
Employment or Leadership Position - Eisai
Takuya Suzuki
Employment or Leadership Position - Eisai